Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Description

This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tumor before and after radiation therapy.

Conditions

Breast Carcinoma, Invasive Breast Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tumor before and after radiation therapy.

Quantifying Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Condition
Breast Carcinoma
Intervention / Treatment

-

Contacts and Locations

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients \>= 18 years of age with biopsy proven invasive breast cancer
  • * Breast cancer that appears to be superficially accessible to a tumor punch biopsy
  • * Patients thought to derive clinical benefit from palliative RT to the breast/chestwall
  • * In discussions with the medical oncologist, if clinically reasonable, systemic therapy will be held during RT
  • * A history of prior radiation to the area requiring radiation for which the attending physician believes reirradiation could not be safely delivered
  • * Pregnancy
  • * Active usage of anticoagulant medications that are considered to pose an increased risk of tumor punch biopsies
  • * Receipt of immunotherapy or chemotherapy 7 days prior to start of RT

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

Simona F Shaitelman, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2026-12-31